Clinical Trial Update: A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 [Phase 3]

View source ↗

Summary

Extension safety study update for mepolizumab in hypereosinophilic syndrome (Phase 3; completed; results posted).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypereosinophilic Syndrome

Drugs mentioned

• Mepolizumab (mepolizumab)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hypereosinophilic Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2020-06-23